# Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy

> **NCT00851565** · PHASE4 · UNKNOWN · sponsor: **Copenhagen University Hospital at Herlev** · enrollment: 120 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **PROCEDURE:** Measurement of serum infliximab and anti-infliximab antibodies
- **PROCEDURE:** Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status

## Key facts

- **NCT ID:** NCT00851565
- **Lead sponsor:** Copenhagen University Hospital at Herlev
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2012-02
- **Final completion:** 2014-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2011-11-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00851565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00851565, "Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00851565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*